Cytomegalic Inclusion DiseaseSymptoms, Doctors, Treatments, Advances & More
Cytomegalic Inclusion Disease Overview
Learn About Cytomegalic Inclusion Disease
Johns Hopkins Health Care & Surgery Center - Green Spring Station, Lutherville
Robin Avery is an Infectious Disease provider practicing medicine in Lutherville, Maryland. Dr. Avery is rated as an Elite provider by MediFind in the treatment of Cytomegalic Inclusion Disease. She is also highly rated in 9 other conditions, according to our data. Her clinical expertise encompasses Cytomegalic Inclusion Disease, Cytomegalovirus Infection, COVID-19, and Severe Acute Respiratory Syndrome (SARS). Dr. Avery is board certified in American Board Of Internal Medicine. Dr. Avery is currently accepting new patients.
Rachel Loschiavo PA-C
Michael Boeckh is an Infectious Disease provider practicing medicine in Seattle, Washington. Dr. Boeckh is rated as an Elite provider by MediFind in the treatment of Cytomegalic Inclusion Disease. He is also highly rated in 10 other conditions, according to our data. His clinical expertise encompasses Cytomegalovirus Infection, Cytomegalic Inclusion Disease, Parainfluenza, and Shingles. Dr. Boeckh is currently accepting new patients.
St Orsola Malpighi University Hospital
Tiziana Lazzarotto practices practicing medicine in Bologna, Italy. Ms. Lazzarotto is rated as an Elite expert by MediFind in the treatment of Cytomegalic Inclusion Disease. She is also highly rated in 12 other conditions, according to our data. Her clinical expertise encompasses Congenital Cytomegalovirus, Cytomegalovirus Infection, Cytomegalic Inclusion Disease, Hepato-Pancreato-Biliary Surgery, and Bone Marrow Transplant.
Summary: This study is a randomized, open-label, active comparator-controlled, dose-ranging trial of the efficacy and safety of IV artesunate in combination with IV GCV or oral VGCV and SOC treatment compared to GCV or VGCV monotherapy and SOC treatment in SOT recipients with clinically significant CMV infection.
Summary: The primary objective is to determine the safety and feasibility of administering R-MVST cells to patients with refractory viral reactivation and/or symptomatic disease caused by Epstein Barr Virus (EBV), cytomegalovirus (CMV), adenovirus (ADV) or BK virus. R-MVST cells will be generated on-demand from the closest partially human leukocyte antigen (HLA)-matched (minimum haploidentical) healthy don...

